Initially touted as a ‘primary’ vaccine to help immunise Australia by the end of this year, Novavax will now form part of the booster strategy
One of the federal government’s key vaccine deals has been hit with major delays, with 51 million doses of Novavax originally due to arrive in the second half of this year now not expected until 2022.
Since initially touting Novavax as one of three secured deals that could immunise the entire population as a “primary” vaccine by the end of this year, the federal government has quietly edged away from the commitment as it focusses instead to securing more Pfizer vaccines.
Related: Supermarket workers in south-west Sydney to get priority access to Pfizer vaccine
